New combo therapy tested to keep breast cancer from returning

NCT ID NCT06930859

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 20 times

Summary

This study is testing how well the drug ribociclib, combined with standard hormone therapy, prevents breast cancer from coming back in people with HR+ HER2- stage II or III breast cancer. About 2,766 participants in Russia will be followed for up to 5 years. The goal is to see if adding ribociclib improves cancer-free survival compared to hormone therapy alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Kaluga, Russia, 248007, Russia
Novartis Investigative Site
RECRUITING

Ryazan, Russia, 390011, Russia
Novartis Investigative Site
RECRUITING

Surgut, Tymen Area, 628402, Russia
Novartis Investigative Site
RECRUITING

Arkhangelsk, 163045, Russia
Novartis Investigative Site
RECRUITING

Barnaul, 656045, Russia
Novartis Investigative Site
RECRUITING

Bryansk, 241028, Russia
Novartis Investigative Site
RECRUITING

Irkutsk, 664035, Russia
Novartis Investigative Site
RECRUITING

Ivanovo, 153040, Russia
Novartis Investigative Site
RECRUITING

Izhevsk, 426009, Russia
Novartis Investigative Site
RECRUITING

Kemerovo, 650036, Russia
Novartis Investigative Site
RECRUITING

Khabarovsk, 680042, Russia
Novartis Investigative Site
RECRUITING

Khanty-Mansiysk, 628012, Russia
Novartis Investigative Site
RECRUITING

Khimky, 121552, Russia
Novartis Investigative Site
RECRUITING

Kirov, 610021, Russia
Novartis Investigative Site
RECRUITING

Krasnoyarsk, 660022, Russia
Novartis Investigative Site
RECRUITING

Moscow, 115304, Russia
Novartis Investigative Site
RECRUITING

Moscow, 115522, Russia
Novartis Investigative Site
RECRUITING

Moscow, 125284, Russia
Novartis Investigative Site
RECRUITING

Moscow, 129110, Russia
Novartis Investigative Site
RECRUITING

Moscow Region Balas, 143900, Russia
Novartis Investigative Site
RECRUITING

Perm, 614066, Russia
Novartis Investigative Site
RECRUITING

Pyatigorsk, 357502, Russia
Novartis Investigative Site
RECRUITING

Rostov-on-Don, 344006, Russia
Novartis Investigative Site
RECRUITING

Saint Petersburg, 194017, Russia
Novartis Investigative Site
RECRUITING

Saint Petersburg, 194291, Russia
Novartis Investigative Site
RECRUITING

Saint Petersburg, 197758, Russia
Novartis Investigative Site
RECRUITING

Saransk, 430032, Russia
Novartis Investigative Site
RECRUITING

Tver', 170008, Russia
Novartis Investigative Site
RECRUITING

Tyumen, 625023, Russia
Novartis Investigative Site
RECRUITING

Ufa, 450054, Russia
Novartis Investigative Site
RECRUITING

Vladikavkaz, 362002, Russia
Novartis Investigative Site
RECRUITING

Vladivostok, 690105, Russia
Novartis Investigative Site
RECRUITING

Volgograd, 400138, Russia
Novartis Investigative Site
RECRUITING

Voronezh, 394036, Russia
Novartis Investigative Site
RECRUITING

Yaroslavl, 150054, Russia
Novartis Investigative Site
RECRUITING

Yekaterinburg, 620036, Russia
Novartis Investigative Site
RECRUITING

Yuzhno-Sakhalinsk, 693010, Russia

Conditions

Explore the condition pages connected to this study.

BREAST CANCER